Reference health

Distinct antibody species: structural differences creating therapeutic opportunities

https://doi.org/10.1016/j.coi.2016.02.003

61/61 checkable references clean · checked 2026-07-22

Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.

2 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.

The 61 checked references that resolve

resolves10.1016/j.jprot.2011.06.019

Research strategies to improve snakebite treatment: Challenges and progress

resolves10.1016/j.copbio.2011.06.002

Non-immunoglobulin based protein scaffolds

resolves10.1016/j.coi.2008.06.004

Fully human antibodies from transgenic mouse and phage display platforms

resolves10.1016/j.jim.2004.04.007

Antibodies from phage antibody libraries

resolves10.1038/nbt1126

Selecting and screening recombinant antibody libraries

resolves10.1016/j.dci.2005.06.010

Antibody repertoire development in camelids

resolves10.1016/j.cell.2013.04.049

Reshaping Antibody Diversity

resolves10.1080/10635150290102311

Resolution of a Supertree/Supermatrix Paradox

resolves10.1038/363446a0

Naturally occurring antibodies devoid of light chains

resolves10.1002/(SICI)1521-4141(199908)29:08<2420::AID-IMMU2420>3.0.CO;2-A

Exceptionally long CDR3H region with multiple cysteine residues in functional bovine IgM antibodies

resolves10.1007/s00251-002-0433-0

Heavy-chain antibodies in Camelidae ; a case of evolutionary innovation

resolves10.1016/S0161-5890(99)00067-X

Loss of splice consensus signal is responsible for the removal of the entire CH1 domain of the functional camel IGG2A heavy-chain antibodies11This work was supported by the VLIR, VIB and FGWO.

resolves10.1046/j.1365-2567.2003.01633.x

Heavy‐chain only antibodies derived from dromedary are secreted and displayed by mouse B cells

resolves10.1007/s002510050694

The structure of the llama heavy chain constant genes reveals a mechanism for heavy-chain antibody formation

resolves10.1093/emboj/19.5.921

Camel heavy‐chain antibodies: diverse germline VHH and specific mechanisms enlarge the antigen‐binding repertoire

resolves10.1006/jmbi.1997.1477

The specific variable domain of camel heavy-chain antibodies is encoded in the germline

resolves10.4049/jimmunol.181.3.2001

Tetrameric and Homodimeric Camelid IgGs Originate from the Same IgH Locus

resolves10.1093/protein/7.9.1129

Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains

resolves10.1038/nsb0996-803

Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme

resolves10.1074/jbc.M111.242818

Dual Beneficial Effect of Interloop Disulfide Bond for Single Domain Antibody Fragments

resolves10.1073/pnas.0505379103

Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies

resolves10.1016/S0959-440X(94)90070-1

Antibody-antigen interactions

resolves10.1016/j.sbi.2015.01.001

Camelid nanobodies: killing two birds with one stone

resolves10.1006/jmbi.2001.4856

Lateral recognition of a dye hapten by a llama VHH domain

resolves10.1038/nsmb.1727

Modulation of protein properties in living cells using nanobodies

resolves10.1042/BJ20131399

Structure of cyclin G-associated kinase (GAK) trapped in different conformations using nanobodies

resolves10.1093/emboj/17.13.3512

Potent enzyme inhibitors derived from dromedary heavy‐chain antibodies

resolves10.1111/j.1538-7836.2011.04495.x

TAFIa inhibiting nanobodies as profibrinolytic tools and discovery of a new TAFIa conformation

resolves10.1042/BJ20121305

Allosteric inhibition of VIM metallo-β-lactamases by a camelid nanobody

resolves10.1016/j.jmb.2011.01.017

Constraining Enzyme Conformational Change by an Antibody Leads to Hyperbolic Inhibition

resolves10.1073/pnas.1301336110

Viral infection modulation and neutralization by camelid nanobodies

resolves10.1128/JVI.03402-13

Mechanism of Action and Capsid-Stabilizing Properties of VHHs with an In Vitro Antipolioviral Activity

resolves10.1083/jcb.201409074

Nanobodies and recombinant binders in cell biology

resolves10.1038/nature13552

X-ray structure of the mouse serotonin 5-HT3 receptor

resolves10.1038/nature10361

Crystal structure of the β2 adrenergic receptor–Gs protein complex

resolves10.1074/mcp.M700342-MCP200

A Versatile Nanotrap for Biochemical and Functional Studies with Fluorescent Fusion Proteins

resolves10.1016/j.copbio.2011.06.007

Engineering antibodies and proteins for molecular in vivo imaging

resolves10.1038/nsmb.2180

Fluorescent fusion protein knockout mediated by anti-GFP nanobody

resolves10.1038/nature15712

Dpp spreading is required for medial but not for lateral wing disc growth

resolves10.1016/j.cell.2013.07.021

A Nanobody-Based System Using Fluorescent Proteins as Scaffolds for Cell-Specific Gene Manipulation

resolves10.1038/nn.4081

Cell type–specific manipulation with GFP-dependent Cre recombinase

resolves10.2967/jnumed.114.143792

99mTc-cAbVCAM1-5 Imaging Is a Sensitive and Reproducible Tool for the Detection of Inflamed Atherosclerotic Lesions in Mice

resolves10.1073/pnas.1502609112

Noninvasive imaging of immune responses

resolves10.1021/nn500212h

Highly Sensitive Single Domain Antibody–Quantum Dot Conjugates for Detection of HER2 Biomarker in Lung and Breast Cancer Cells

resolves10.2967/jnumed.115.162024

Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma

resolves10.1002/ijc.26145

A biparatopic anti‐EGFR nanobody efficiently inhibits solid tumour growth

resolves10.2217/nnm.14.178

Nanobody-Based Cancer Therapy of Solid Tumors

resolves10.7150/thno.8156

Targeted Radionuclide Therapy with A 177Lu-labeled Anti-HER2 Nanobody

resolves10.1074/jbc.M806889200

General Strategy to Humanize a Camelid Single-domain Antibody and Identification of a Universal Humanized Nanobody Scaffold

resolves10.1007/s10875-013-9915-0

Autoantibodies to Variable Heavy (VH) Chain Ig Sequences in Humans Impact the Safety and Clinical Pharmacology of a VH Domain Antibody Antagonist of TNF-α Receptor 1

resolves10.1007/s00280-015-2712-0

Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor

resolves10.1007/s12265-012-9435-y

Novel Antiplatelet Agents: ALX-0081, a Nanobody Directed towards von Willebrand Factor

resolves10.1080/19420862.2015.1046648

Camelid Ig V genes reveal significant human homology not seen in therapeutic target genes, providing for a powerful therapeutic antibody platform

resolves10.1016/S0161-5890(03)00098-1

Unusually long germline DH genes contribute to large sized CDR3H in bovine antibodies

resolves10.1093/intimm/dxg083

Bovine IgM antibodies with exceptionally long complementarity‐determining region 3 of the heavy chain share unique structural properties conferring restricted VH + Vλ pairings

resolves10.1016/j.vetimm.2011.10.001

Somatic hypermutation leads to diversification of the heavy chain immunoglobulin repertoire in cattle

resolves10.1016/j.sbi.2015.06.002

Structural and genetic diversity in antibody repertoires from diverse species

resolves10.1021/cb4004749

An Antibody CDR3-Erythropoietin Fusion Protein

resolves10.1002/anie.201303656

Functional Antibody CDR3 Fusion Proteins with Enhanced Pharmacological Properties

resolves10.1002/anie.201307939

An Antibody with a Variable‐Region Coiled‐Coil “Knob” Domain

resolves10.1073/pnas.1423668112

Functional human antibody CDR fusions as long-acting therapeutic endocrine agonists

The 2 references without a DOI — listed, not checked

no DOI — not checkedAdverse reactions to snake antivenom, and their prevention and treatment

no DOI — not checkedRadiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer [Internet]

What this badge says. CiteStamped means the CHECKABLE references of this work were clean at the dated check: each resolved to a known work in a public registry, and none carried a retraction notice at that time. It says nothing about the quality, findings, or importance of the work itself, and nothing about references deposited without a DOI.

checked 2026-07-22 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record

view as graph · paper page

Embed this badge

Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.

<a href="https://citestamp.com/citestamped/10.1016/j.coi.2016.02.003"><img src="https://citestamp.com/citestamped/10.1016/j.coi.2016.02.003/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>

[![CiteStamped reference-health badge](https://citestamp.com/citestamped/10.1016/j.coi.2016.02.003/badge.svg)](https://citestamp.com/citestamped/10.1016/j.coi.2016.02.003)